Literature DB >> 15355515

Regulation of myosin-VI targeting to endocytic compartments.

Amber L Dance1, Matthew Miller, Shinobu Seragaki, Prafulla Aryal, Breanne White, Laura Aschenbrenner, Tama Hasson.   

Abstract

Myosin-VI has been implicated in endocytic trafficking at both the clathrin-coated and uncoated vesicle stages. The identification of alternative splice forms led to the suggestion that splicing defines the vesicle type to which myosin-VI is recruited. In contrast to this hypothesis, we find that in all cell types examined, myosin-VI is associated with uncoated endocytic vesicles, regardless of splice form. GIPC, a PDZ-domain containing adapter protein, co-assembles with myosin-VI on these vesicles. Myosin-VI is only recruited to clathrin-coated vesicles in cells that express high levels of Dab2, a clathrin-binding adapter protein. Overexpression of Dab2 is sufficient to reroute myosin-VI to clathrin-coated pits in cells where myosin-VI is normally associated with uncoated vesicles. In normal rat kidney (NRK) cells, which express high endogenous levels of Dab2, splicing of the globular tail domain further modulates targeting of ectopically expressed myosin-VI. Although myosin-VI can be recruited to clathrin-coated pits, we find no requirement for myosin-VI motor activity in endocytosis in NRK cells. Instead, our data suggest that myosin-VI recruitment to clathrin-coated pits may be an early step in the recruitment of GIPC to the vesicle surface.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355515     DOI: 10.1111/j.1600-0854.2004.00224.x

Source DB:  PubMed          Journal:  Traffic        ISSN: 1398-9219            Impact factor:   6.215


  44 in total

Review 1.  Principles of unconventional myosin function and targeting.

Authors:  M Amanda Hartman; Dina Finan; Sivaraj Sivaramakrishnan; James A Spudich
Journal:  Annu Rev Cell Dev Biol       Date:  2011-05-31       Impact factor: 13.827

2.  Effects of loss of myosin VI no-insert isoform on clathrin-mediated endocytosis of plasma-membrane receptors.

Authors:  Claudia Puri
Journal:  Commun Integr Biol       Date:  2010-05

3.  Myosin VI must dimerize and deploy its unusual lever arm in order to perform its cellular roles.

Authors:  Monalisa Mukherjea; M Yusuf Ali; Carlos Kikuti; Daniel Safer; Zhaohui Yang; Helena Sirkia; Virginie Ropars; Anne Houdusse; David M Warshaw; H Lee Sweeney
Journal:  Cell Rep       Date:  2014-08-21       Impact factor: 9.423

Review 4.  Mechano-electrical transduction: new insights into old ideas.

Authors:  A J Ricci; B Kachar; J Gale; S M Van Netten
Journal:  J Membr Biol       Date:  2006-05-25       Impact factor: 1.843

5.  Internalization of large double-membrane intercellular vesicles by a clathrin-dependent endocytic process.

Authors:  Michelle Piehl; Corinna Lehmann; Anna Gumpert; Jean-Pierre Denizot; Dominique Segretain; Matthias M Falk
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

6.  Negative regulation of the endocytic adaptor disabled-2 (Dab2) in mitosis.

Authors:  David Chetrit; Lior Barzilay; Galit Horn; Tom Bielik; Nechama I Smorodinsky; Marcelo Ehrlich
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

7.  A PDZ-binding motif as a critical determinant of Rho guanine exchange factor function and cell phenotype.

Authors:  Miaoliang Liu; Arie Horowitz
Journal:  Mol Biol Cell       Date:  2006-02-08       Impact factor: 4.138

Review 8.  Receptor-Mediated Endocytosis in the Proximal Tubule.

Authors:  Megan L Eshbach; Ora A Weisz
Journal:  Annu Rev Physiol       Date:  2016-10-28       Impact factor: 19.318

9.  Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene.

Authors:  Hongyu Ying; Xiang Shen; BumChan Park; Beatrice Y J T Yue
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

10.  Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.

Authors:  C Puri; M V Chibalina; S D Arden; A J Kruppa; J Kendrick-Jones; F Buss
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.